Home Other Building Blocks 6,7-Dimethyl-2-phenylquinoxaline

6,7-Dimethyl-2-phenylquinoxaline

CAS No.:
71897-07-9
Catalog Number:
AG005P7S
Molecular Formula:
C16H14N2
Molecular Weight:
234.2958
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1mg
≥98%
1 week
United States
$91
- +
5mg
≥98%
1 week
United States
$169
- +
10mg
≥98%
1 week
United States
$265
- +
25mg
≥98%
1 week
United States
$491
- +
Product Description
Catalog Number:
AG005P7S
Chemical Name:
6,7-Dimethyl-2-phenylquinoxaline
CAS Number:
71897-07-9
Molecular Formula:
C16H14N2
Molecular Weight:
234.2958
MDL Number:
MFCD00270912
IUPAC Name:
6,7-dimethyl-2-phenylquinoxaline
InChI:
InChI=1S/C16H14N2/c1-11-8-14-15(9-12(11)2)18-16(10-17-14)13-6-4-3-5-7-13/h3-10H,1-2H3
InChI Key:
FQNCLVJEQCJWSU-UHFFFAOYSA-N
SMILES:
Cc1cc2ncc(nc2cc1C)c1ccccc1
NSC Number:
380341
Properties
Complexity:
272  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
234.116g/mol
Formal Charge:
0
Heavy Atom Count:
18  
Hydrogen Bond Acceptor Count:
2  
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
234.302g/mol
Monoisotopic Mass:
234.116g/mol
Rotatable Bond Count:
1  
Topological Polar Surface Area:
25.8A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.6  
Literature
Title Journal
AhR-dependent secretion of PDGF-BB by human classically activated macrophages exposed to DEP extracts stimulates lung fibroblast proliferation. Toxicology and applied pharmacology 20150615
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. The Biochemical journal 20130415
Inhibitory effects of resveratrol on PDGF-BB-induced retinal pigment epithelial cell migration via PDGFRβ, PI3K/Akt and MAPK pathways. PloS one 20130101
Platelet-derived growth factor receptor kinase inhibitor AG-1295 promotes osteoblast differentiation in MC3T3-E1 cells via the Erk pathway. Bioscience trends 20120601
N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation. Bioorganic & medicinal chemistry 20120401
HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers. Cancer research 20111101
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nature biotechnology 20111101
PDGF-β receptor and PKC have no effect on angiotensin II-induced JAK2 and STAT1 phosphorylation in vascular smooth muscle cells under high glucose condition. Journal of receptor and signal transduction research 20111001
The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines. Bioorganic & medicinal chemistry letters 20100515
Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors. Bioorganic & medicinal chemistry 20091015
FGF2 is crucial for the development of bovine luteal endothelial networks in vitro. Reproduction (Cambridge, England) 20090901
Bovine lactoferrin stimulates human corneal epithelial alkali wound healing in vitro. Investigative ophthalmology & visual science 20090401
BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3. Blood 20090305
Modulation of circadian rhythm of DNA synthesis in tumor cells by inhibiting platelet-derived growth factor signaling. Journal of pharmacological sciences 20080801
Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents. Bioorganic & medicinal chemistry 20080515
Potentiation by platelet-derived growth factor-BB of FGF-2-stimulated VEGF release in osteoblasts. Journal of bone and mineral metabolism 20080101
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proceedings of the National Academy of Sciences of the United States of America 20071218
Platelet-derived growth factors and receptors in the rat corpus luteum: localization and identification of an effect on luteogenesis. Biology of reproduction 20070301
Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorganic & medicinal chemistry 20070301
Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. Journal of medicinal chemistry 20060601
Microsphere-based protease assays and screening application for lethal factor and factor Xa. Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
The role of platelet-derived growth factor receptor in eotaxin signaling of eosinophils. International archives of allergy and immunology 20060101
Nicotinic and PDGF-receptor function are essential for nicotine-stimulated mitogenesis in human vascular smooth muscle cells. Journal of cellular biochemistry 20051201
Specific locations of hydrophilic amino acids in constructed transmembrane ligands of the platelet-derived growth factor beta receptor. Journal of molecular biology 20050128
Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis. Blood 20050101
Signal transduction of c-Kit receptor tyrosine kinase in CHRF myeloid leukemia cells. Journal of cancer research and clinical oncology 20041201
Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. Blood 20040315
Differential roles of WAVE1 and WAVE2 in dorsal and peripheral ruffle formation for fibroblast cell migration. Developmental cell 20031001
Signaling and distribution of NPR-Bi, the human splice form of the natriuretic peptide receptor type B. American journal of physiology. Renal physiology 20030801
Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. Oncogene 20030417
UVB-induced apoptosis in normal human keratinocytes: role of the erbB receptor family. Experimental cell research 20030401
PDGF and FGF2 regulate oligodendrocyte progenitor responses to demyelination. Journal of neurobiology 20030215
Platelet-derived growth factor up-regulates the expression of transcription factors NF-E2, GATA-1 and c-Fos in megakaryocytic cell lines. Cytokine 20030121
Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy. Japanese journal of ophthalmology 20030101
Ligand-independent trans-activation of the platelet-derived growth factor receptor by reactive oxygen species requires protein kinase C-delta and c-Src. The Journal of biological chemistry 20021122
Inhibition of aortic allograft vasculopathy by local delivery of platelet-derived growth factor receptor tyrosine-kinase blocker AG-1295. Transplantation 20021115
Study of the drug release mechanism from tyrphostin AG-1295-loaded nanospheres by in situ and external sink methods. Journal of controlled release : official journal of the Controlled Release Society 20021030
Inhibition of platelet-derived growth factor actions in the embryonic testis influences normal cord development and morphology. Biology of reproduction 20020301
Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase. Journal of medicinal chemistry 20020227
Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model. Arteriosclerosis, thrombosis, and vascular biology 20010901
A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 20010801
Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer research 19941201
Properties